Sanofi Pasteur, a vaccine business of Sanofi, is to open an additional influenza production plant in Swiftwater, Pennsylvania. The US FDA Centre of Biologics Evaluation and Research has granted approval for additional manufacturing at the newly completed $425m plant. The investment will create up to 200 manufacturing jobs and will initially commercialise products for the US market, with plans to expand to additional countries.

Elaine O’Hara, head of North America commercial operations for Sanofi Pasteur, said: “We are experiencing fast-growing demand for our vaccine in the US and globally, given the ten years of data demonstrating protection from flu and its related complications.”